Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06080659
Recruiting Not applicable

Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity

NCT06080659 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-11-06
Last updated
2026-01-05

Condition(s) studied

Alzheimer Disease, Early OnsetParkinson Disease

Investigational drug(s) / intervention(s)

fMRICONFMEM

fMRI: functional MRI

CONFMEM: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Study summary

The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * For all participants: * French mother tongue * right-handed * with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate) * Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients) * Affiliated with a social security scheme * Having received oral and written information about the protocol and having signed a consent form to participate in this research. DCS+ group: \- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014). Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA": \- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011)) De novo" Parkinsonian patients, "MPdn": \- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015)) Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP": \- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012)) Exclusion Criteria: * All participants (healthy volunteers and patients) * Contraindications to MRI : * Abdominal circumference + upper limbs sticking to the body \> 200 cm; * Implantable pacemaker or defibrillator; * Neurosurgical clips; * Cochlear implants ; * Neural or peripheral stimulator; * Intra-orbital or encephalic metallic foreign bodies; * Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; * Claustrophobia. * Pregnant or breast-feeding women; * Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty. Patients only * Score \>2 on the modified Hachinski scale (Hachinski et al., 2012) * Dementia according to McKhann criteria (McKhann et al., 2011) * Sensory deficit interfering with experimental tests Healthy volunteers only \- Cognitive impairment (MoCA score \< 26)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Rennes Rennes France Recruiting

More Rennes University Hospital trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06080659 on ClinicalTrials.gov ↗ ← All trials in France